At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Texas based CFO’ operating in the Therapeutics space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.

Jim Berend
Chief Financial Officer & Executive Vice President of USMD
Jim Berend serves as chief financial officer and executive vice president of USMD Holdings. In his position, Jim oversees all of USMD’s finance functions and activities. Jim has more than 35 years of experience in healthcare finance, having served as a CFO, consultant, auditor and partner at international accounting and consulting firms. He has extensive experience in all aspects of healthcare accounting and finance across the care continuum. Previously, Jim served as CFO and executive vice president of a company operating surgical hospitals in Texas. He was responsible for finance and accounting, centralized billing office, materials management and hospital financial operations.Jim received his Bachelor of Business Administration, with highest honors, from The University of Texas in Austin. He is a licensed CPA in Texas.
Follow Jim Berend:
About USMD: USMD Holdings develops, operates and manages entities that deliver diagnostic, therapeutic and hospital-based health care to patients.
Charles Garner
Chief Financial Officer of Lung Therapeutics
Chuck Garner joined Lung Therapeutics in 2018 as Chief Financial Officer. Mr. Garner brings over 20 years of investment banking, corporate finance, business development and financial operational experience to Lung Therapeutics. Most recently, Mr. Garner was a life sciences industry consultant to private and public life sciences companies, providing financial and advisory services. Prior to this, Mr. Garner was Chief Financial Officer and Chief Business Officer for Recro Pharma, Inc., successfully leading the company’s initial public offering and acquisition of select assets from Alkermes, plc. Mr. Garner began his professional career as a certified public accountant with PricewaterhouseCoopers and, while an investment banker for Deutsche Bank AG, raised or advised on over $8 billion of financial and advisory transactions for healthcare clients. Mr. Garner received his Bachelors of Business Administration, high distinction, with a concentration in accounting and finance from the University of Michigan.
Follow Charles Garner:
About Lung Therapeutics: Lung Therapeutics provides innovative treatments for underserved, life-threatening lung conditions.

Daniel Gutschenritter
Chief Financial Officer of MedMark Treatment Centers
Dan Gutschenritter is EVP & Chief Financial Officer of BayMark Health Services,. Dan joined MedMark Services as Chief Financial Officer in October 2012. He has over twenty years of experience in the fields of finance and operations management. Priorto MedMark, Dan had been the Chief Financial Officer for Medical Clinic of North Texas, P.A. (MCNT). Other roles include serving as the Chief Financial Officer and Administrative Officer of Partners Imaging LP, a company which developed and managed imaging joint ventures with physician groups. Dan has extensive experience working in both public and private equity backed organizations having raised in excess of $350 million in new capital over the course of his career. Dan received his MBA from the Fuqua School of Business at Duke University and completed his undergraduate work at the University of Wisconsin.
Follow Daniel Gutschenritter:
About BayMark Health Services, MedMark Treatment Centers: MedMark Treatment Centers is a pharmacy company that provides specialized pharmacy care to patients with unique or chronic medication.
Joy Nassif
Chief Financial Officer of ANIZOME
Ms. Nassif has over 20 years’ experience in financial and executive management in the healthcare, diagnostic testing, and pharmaceutical industries. Her career has included demonstrated ability to maximize return on investment through aggressive working capital and operating expense management. Additionally, she has experience in building and operationalizing start-up corporations. She currently serves as the Chief Operating Officer of Diversigen, Inc. where she leads all aspects of the company’s sales, marketing, and operational efforts. In the years prior to joining Diversigen, Ms. Nassif held leadership positions at Quest Diagnostics as Vice President of Clinical Trials, and Vice President of Anatomic Pathology. During her tenure at Quest Diagnostics, she developed the strategy for the pharmaceutical division, led the transformation of the international clinical trials business from loss making to profit, and launched the first profitable product in cytology for the company. She obtained a Green Belt in Six Sigma Quality. Ms. Nassif held the positions of Chief Financial Officer and Chief Operating Officer of Franklin Heath, Inc. (A Corning Company). She was responsible for all aspects of operations and administration for this start-up healthcare company. Additionally, Ms. Nassif was director of Finance for Covance, Inc. working in its Phase II-III contract research organization. There, she had international responsibilities for pricing, contracts, revenue recognition, and budgeting. Ms. Nassif graduated summa cum laude from Kean University with a BS in Accounting. She is a Certified Public Accountant. In addition to her corporate positions, she has served on the Board of Advisors for several non-profit groups and organizations.
Follow Joy Nassif:
About ANIZOME: ANIZOME is a microbiome platform company dedicated to improving animal health by translating cutting-edge research.
Daniel Clark
Interim Chief Financial Officer of Kiromic Biopharma
On September 30, 2021, the Board of Directors of the Company appointed Dan Clark as interim Chief Financial Officer, effective September 30, 2021. Mr. Clark joined the Company in February 2020 and served as the Company’s Corporate Controller until September 2021, when he was promoted to Vice President – Finance Operations prior to his appointment as interim Chief Financial Officer. Before joining the Company, Mr. Clark was a Manager with The Siegfried Group, a national accounting services firm, from June 2018 to February 2020. Prior to his employment with The Siegfried Group, Mr. Clark served as Senior Consultant – Office of the CFO Solutions for FTI Consulting, a global financial consulting firm, from January 2017 to May 2018. Prior to that, Mr. Clark was Senior Associate – Audit at KPMG US, a member of Big Four global accounting firm KPMG, from August 2011 to June 2015.
Follow Daniel Clark:
About Kiromic Biopharma: Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs for solid tumors and hematologic malignancies.